Vogt A, Woodhams B, Marbet G A
Gerinnungslaboratorium ZL, Kantonsspital Basel.
Schweiz Med Wochenschr. 1993 Jan 23;123(3):74-6.
A recombinant tissue factor (rTF, Batch TFS-RD3, Baxter Diagnostics) has been assessed by plasma and capillary blood methods and compared with our working rabbit brain thromboplastin (CRB Roche, Basel, Switzerland) for its suitability in monitoring oral anticoagulant therapy. The international sensitivity index (ISI) for rTF calibrated against CRB has been found to be 0.73 and 0.69 respectively. The slope of the orthogonal regression line between log prothrombin time rTF plasma and rTF capillary blood is 0.96. Thus, we considered the ISI to be identical for both methods. International normalized ratios calculated with these assumptions, and even activity percentages assigned by a dilution curve, did not differ from the results obtained with our working thromboplastin. The human recombinant thromboplastin TFS-RD3 seems to have properties similar to currently used commercial thromboplastins. Recombinant tissue factor as a well defined preparation could make essential contributions to the standardization of prothrombin time and to the improvement of oral anticoagulant therapy.
一种重组组织因子（rTF，批号TFS-RD3，百特诊断公司）已通过血浆和毛细血管血方法进行评估，并与我们的工作用兔脑凝血活酶（CRB，罗氏公司，瑞士巴塞尔）比较其在监测口服抗凝治疗中的适用性。以CRB校准的rTF的国际敏感指数（ISI）分别为0.73和0.69。rTF血浆的对数凝血酶原时间与rTF毛细血管血之间的正交回归线斜率为0.96。因此，我们认为两种方法的ISI相同。基于这些假设计算的国际标准化比值，以及通过稀释曲线确定的活性百分比，与使用我们的工作凝血活酶获得的结果没有差异。人重组凝血活酶TFS-RD3似乎具有与目前使用的商业凝血活酶相似的特性。重组组织因子作为一种明确界定的制剂，可为凝血酶原时间的标准化以及口服抗凝治疗的改进做出重要贡献。
